Nightingale Solutions Ltd Website Launched

Website_LaunchedNightingale Solutions Ltd has collaborated with Charles Abdilla Web Design to provide a comprehensive source of company information and services.

The website features a design focused on delivering information pertaining to services in an easy to navigate, aesthetically pleasing approach. The fusion of style and content provides customers to access as well latest news in the health sector and a more clear depiction of many services that Nightingale Solutions Ltd has incorporated to better serve customers.

 

Flu Prevention: Vaccines

Flu_Prevention_Vaccines

Get a flu vaccine. They're made of harmless versions of flu virus to help your body recognize and fight it if exposed to the real thing. Despite what you may hear, they don't give you the flu.

They're especially important for children older than 6 months, pregnant women, adults older than 50, and people with chronic illness or suppressed immune systems.

Healthy children 2 years old and older and non-pregnant healthy adults under 50 can opt for the nasal mist vaccine.

 

FDA Panel Backs New Type of Diabetes Drug

Jan. 16, 2013 -- An FDA advisory panel has given its blessing to canagliflozin (Invokana) for the treatment of type 2 diabetes.

diabetes_drugThe panel voted 10 to 5 in favor of the drug’s approval, but did express concern about heart and stroke risks. The FDA is not obligated to follow the advice of its panels, but it usually does. The FDA is expected to give its decision in March.

Taken by mouth once a day, the drug could be the first in a new class of diabetes drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. Canagliflozin works to reduce the amount of blood sugar (glucose) reabsorbed by the kidneys. This results in glucose being expelled in the urine.

Preliminary data suggest that people who take the new medication have lower glucose levels and also lose weight. Studies of the new drug are ongoing.

Safety Concerns Linger

Despite recommending approval of the new drug, panel members expressed concerns about risks of heart disease and stroke. But data on studies evaluating this risk were insufficient.

They also expressed concerns about the use and safety of this drug in people with kidney disease. As such, some panel members recommended that people with kidney damage do not use this drug if it is approved.

In January 2012, the FDA voted against another SGLT2 inhibitor, dapagliflozin, due to concerns about a cancer risk. This drug was approved in the European Union in November 2012. There is no cancer risk seen with canagliflozin.